(Reuters) - Merck, whose results were also spurred by soaring vaccine sales, really gave investors something to cheer about when it boosted its 2007 earnings forecast 25 cents per share and significantly raised the outlook for sales of several of its drugs, sending its stock up more than 8 percent.
For vaccines alone -- including Gardasil, the first vaccine to protect against cervical cancer -- Merck raised its sales forecast for the year by $600 million to between $3.9 billion and $4.3 billion.
Read more at Reuters.com Business News
For vaccines alone -- including Gardasil, the first vaccine to protect against cervical cancer -- Merck raised its sales forecast for the year by $600 million to between $3.9 billion and $4.3 billion.
Read more at Reuters.com Business News
No comments:
Post a Comment